[1] |
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance,Epidemiology, and End Results Program[J]. Cancer, 2009, 115(7):1531-43. doi: 10.1002/cncr.v115:7
|
[2] |
Posthumadeboer J, Witlox MA, Kaspers G, et al. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature[J]. Clin Exp Metastasis, 2011, 28(5): 493-503. doi: 10.1007/s10585-011-9384-x
|
[3] |
Vives V, Su J, Zhong S, et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth[J].Genes Dev, 2006, 20(10): 1262-7. doi: 10.1101/gad.374006
|
[4] |
Samuels LY, O'connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53[J]. Mol Cell,2001, 8(4): 781-94. doi: 10.1016/S1097-2765(01)00367-7
|
[5] |
Wang YH, Bu FF, Royer C, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1[J]. Nat Cell Biol, 2014, 16(11): 1092-6. doi: 10.1038/ncb3050
|
[6] |
朱泳鹏, 王东军, 何友虎. 人脑胶质瘤中ASPP1和ASPP2蛋白的表达及其与细胞凋亡的相关性[J]. 广东医学, 2012, 33(13): 1964-8. http://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201213049.htm
|
[7] |
Li SJ, Shi GX, Yuan H, et al. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP[J]. Oncol Rep, 2012, 28(1): 133-40. http://cn.bing.com/academic/profile?id=32b9feafc3c97449e7c15834935e8a06&encoded=0&v=paper_preview&mkt=zh-cn
|
[8] |
Sgroi DC, Teng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression[J]. Cancer Res,1999, 59(22): 5656-61. http://cn.bing.com/academic/profile?id=a0c1ee79a9eab9e7cac1cb48386d4c68&encoded=0&v=paper_preview&mkt=zh-cn
|
[9] |
Meng WD, Chu RX, Wang BZ, et al. Helicobacter pylori infection and expressions of apoptosis-related proteins p53, ASPP2 and iASPP in gastric cancer and precancerous lesions[J]. Pathol Biol (Paris), 2013, 61(5): 199-202. doi: 10.1016/j.patbio.2013.02.002
|
[10] |
苏敏, 谷宇, 苏胜发, 等. p53凋亡刺激蛋白家族蛋白表达与非小细胞肺癌患者预后的关系[J]. 中华肿瘤杂志, 2014, 36(4): 268-72. http://cn.bing.com/academic/search?q=%e4%b8%ad%e5%8d%8e%e8%82%bf%e7%98%a4%e6%9d%82%e5%bf%97&FORM=AJOUR
|
[11] |
Gozo MC, Jia DY, Aspuria PJ, et al. FOXC2 augments tumor propagation and metastasis in osteosarcoma[J]. Oncotarget, 2016, 7(42): 68792-802. http://cn.bing.com/academic/profile?id=aacb214b01889de1cfa8d0281fdff625&encoded=0&v=paper_preview&mkt=zh-cn
|
[12] |
Liu HL, Zhi LQ, Duan N, et al. Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients[J]. FEBS Open Bio, 2016, 6(8):807-15. doi: 10.1002/2211-5463.12079
|
[13] |
Mak VC, Lee L, Siu MK, et al. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation[J]. Carcinogenesis, 2013,34(9): 2170-7. doi: 10.1093/carcin/bgt161
|
[14] |
Chang YW, Su YJ, Hsiao M, et al. Diverse targets of beta-Catenin during the Epithelial-Mesenchymal transition define cancer stem cells and predict disease relapse[J]. Cancer Res, 2015, 75(16):3398-410. doi: 10.1158/0008-5472.CAN-14-3265
|
[15] |
Varisli L, Ozturk BE, Akyuz GK, et al. HN1 negatively influences the beta-Catenin/E-Cadherin interaction, and contributes to migration in prostate cells[J]. J Cell Biochem, 2015, 116(1): 170-8. doi: 10.1002/jcb.v116.1
|
[16] |
Lee K, Lindsey AS, Li N, et al. Beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG[J]. Oncotarget, 2016, 7(5):5353-65. http://cn.bing.com/academic/profile?id=d7c8a1c3a120ff20566b27f19f006564&encoded=0&v=paper_preview&mkt=zh-cn
|
[17] |
Jin RS, Liu WS, Menezes S, et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of beta-catenin through mechanisms involving FRAT1 and PAK4 [J]. J Cell Sci, 2014, 127(14): 3116-30. doi: 10.1242/jcs.147835
|